Navigation Links
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
Date:2/19/2009

.0 million, reflecting the launch of new products. Generic other revenue decreased $28.0 million to $2.1 million, due primarily to a decline in royalties related to Sandoz's sales of metoprolol succinate extended-release tablets 50mg.

Generic gross profit was $153.0 million, or 41.7 percent of revenue, in the fourth quarter of 2008, compared to $149.9 million in the fourth quarter of 2007 and $151.4 million in the third quarter of 2008. Generic gross profit was positively influenced by certain new products, including omeprazole delayed-release capsules 40mg and transdermal fentanyl, which was offset by lower other revenue. Generic gross profit for the fourth quarter 2008 reflects approximately $6.0 million in costs related to Watson's Global Supply Chain Initiative. Excluding this item, Generic gross profit was $159.0 million, or 43.3 percent of revenue in the fourth quarter 2008.

Generic research and development expense increased $10.4 million to $35.8 million, reflecting an acceleration in activities following rationalization of the development portfolio. Watson currently has approximately 60 ANDAs on file, including tentative approvals.

For the full year 2008, Generic product sales were essentially unchanged at $1.40 billion. An increase of new product launches, including the launch of omeprazole delayed-release capsules 40mg and increased sales of transdermal fentanyl was offset by a loss in revenue from oxycodone HCl extended-release tablets. Generic other revenue decreased $22.6 million to $70.4 million due primarily to a decline in royalties related to Sandoz's sales of metoprolol succinate extended-release tablets 50mg.

Generic gross margin increased from 38.9 percent in 2007 to 40.1 percent in 2008, due to enhanced operational efficiencies and an improved product mix. Generic gross profit for 2008 reflects approximately $27.8 million in costs related to Watson's Global Supp
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
2. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
3. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
4. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
5. U.S. Workers Taking Steps to Lower Medical Costs, Watson Wyatt Survey Finds
6. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
7. Driving Consumer Engagement Is Focus of Address by Healthfitness Chief Medical Officer at Watson Wyatt Health Care Solutions Event
8. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
9. Watson Enters Into Agreement to Acquire Products Related to Tevas Proposed Acquisition of Barr
10. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
11. Watson Pharmaceuticals Reports Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Steven Reinberg ... News) -- In a head-to-head comparison, an experimental drug ... and hospitalizations in heart failure patients. According to ... of the marked benefit of the new drug, dubbed ... those getting the standard medication, enalapril (Vasotec), either died ...
(Date:9/1/2014)... An operating theatre or operating room is ... operations. An operating room comprises a myriad of specially-designed ... lights, imaging displays as well as integration systems for ... Research, a U.S.-based market research firm, the operating room ... by 2019. , According to this report, the ...
(Date:9/1/2014)... Barcelona, Spain Monday 1 September 2014: Daily fruit ... up to 40%, according to research presented at ESC ... The findings from the seven year follow-up study of ... found that the more fruit people ate, the more ... "CVD, including ischaemic heart disease (IHD) and stroke, is ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Bioinformatics ... organize and analyze biological and genetic data. A ... activity of developing software tools to generate and ... be confused with biological computation. While bioinformatics simply ... of biology can its related concepts, biological computation ...
(Date:9/1/2014)... 2014 Ontraport , one of ... was developed to automate the small intricacies of managing ... Shane Michaels, prompting an investigative review. , “As ... of managing all of the small details involved with ... reports Michaels. “That’s why Ontraport has become so popular ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2
... , , , ... part of Mayo Clinic and Microsoft Corp.,s shared vision to help ... made enhancements to Mayo Clinic Health Manager , ... manage their health. People with conditions such as hypertension and high ...
... Germany: For the first time researchers have shown that by ... possible to make pancreatic cancer cells sensitive to chemotherapy, opening ... treat the disease. Dr Davide Melisi told Europe,s ... Berlin today (Thursday 24 September) that resistance to chemotherapy was ...
... New Series ... iPod touch. , ... (Vocus) September 24, 2009 -- Modality, Inc. and Elsevier, Inc. today announced two Procedures Consult ... help physicians, medical residents and students prepare for, perform and test their knowledge of the ...
... ... leader in automatic door sensors, BEA, Inc. is delighted our products will be welcoming ... center in the world with Gold LEED® (Leadership in Energy and Environmental Design) certification. ... Pittsburgh, Pa. ...
... ... is featured in a presentation and free downloadable slides on the Diabetes Best Practices ... Somerville, ... illnesses should focus on self-care and give them the survival skills necessary to maintain ...
... AMSTERDAM, September 24 Amsterdam Molecular,Therapeutics (Euronext: AMT), a ... Jorn Aldag as its new Chief Executive Officer, starting,October ... in the life,sciences sector and more than twenty five ... President and CEO of Evotec AG, he was,instrumental in ...
Cached Medicine News:Health News:Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol 2Health News:Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol 3Health News:Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy 2Health News:Procedures Consult Internal Medicine Applications Now Available on App Store 2Health News:Procedures Consult Internal Medicine Applications Now Available on App Store 3Health News:BEA Opens the Doors to the World at G20 Summit 2Health News:BEA Opens the Doors to the World at G20 Summit 3Health News:New Presentation Highlights Importance of In-Hospital Hyperglycemia Management and Appropriate Discharge Planning for Diabetes Patients 2Health News:AMT Appoints New Chief Executive Officer 2Health News:AMT Appoints New Chief Executive Officer 3
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
(Date:8/29/2014)... PLEASANTON, Calif. , Aug. 29, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... be participating in the 2014 Morgan Stanley Global Healthcare ... F. Burbach , President and Chief Executive Officer, will ... p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Time). ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the measurement of vaginal pH as part of a self examination programme to help reduce the risk of pre-term birth...
Medicine Products: